SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- HIV -- Ignore unavailable to you. Want to Upgrade?


To: idos who wrote (103)8/13/2009 6:12:31 PM
From: DewDiligence_on_SI  Read Replies (2) | Respond to of 155
 
Isentress is a fine drug, but it's a BID in a qD world.



To: idos who wrote (103)4/9/2010 12:55:11 PM
From: tuck  Read Replies (1) | Respond to of 155
 
Merck now working on a dual ccr5/ccr2 antagonist:

"Discovery of a Potent and Orally Bioavailable CCR2 and CCR5 Dual Antagonist"

pubs.acs.org

Full text freebie from the inaugural issue of ACS Medicinal Chemistry Letters.

Cheers, Tuck